AbCellera Biologics has revealed a new $700-million project that will add research and development capacity to the manufacturing plant that has been in the works since 2020.

'Our goal is to reach the most high-risk COVID-positive patients, to prevent them from getting so sick that they end up hospitalized or dying,' says Dr. Zain Chagla.